Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

British Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2009, Pages 61-76

  Lowe, Philip J ^a   Tannenbaum, Stacey ^a   Gautier, Aurelie ^a   Jimenez, Pablo ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asthma; Binding; IgE; NONMEM; Omalizumab

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEVERE PERSISTENT ASTHMA; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 67650938578     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03401.x     Document Type: Article

References (37)

1. World Health Organization. The European Health Report. Geneva : World Health Organization, 2002.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004 59 : 469 78.
3. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002 109 : S482 9.
4. European Respiratory Society and the European Lung Foundation. European Lung White Book. Brussels, Belgium : European Respiratory Society and the European Lung Foundation, 2003.
5. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003 112 : 252 62.
6. Ishizaka K, Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 1967 99 : 1187 98.
7. Johansson SGO, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967 13 : 381 94.
8. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989 320 : 271 7.
9. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005 115 : 459 65.
10. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003 111 : S486 94.
11. Presta L, Shields R, O'Connell L, Lahr S, Porter J, Gorman C, Jardieu P. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994 269 : 26368 73.
12. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. Humanization of an antibody directed against IgE. J Immunol 1993 151 : 2623 32.
13. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramo S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005 60 : 309 16.
14. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005 60 : 302 8.
15. Corren J, Casale T, Lanier BQ, Blogg M, Reisner C, Gupta N. Omalizumab is well tolerated in adolescent/adult patients (≥12 years) with moderate-to-severe persistent asthma. J Allergy Clin Immunol 2005 115 : S75 (abstract).
16. Omalizumab, Xolair, label information. http://www.fda.gov/cder/foi/label/ 2003/omalgen062003LB.pdf.
17. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996 279 : 1000 8.
18. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995 34 : 10474 82.
19. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996 26 : 690 6.
20. Mariani G, Strober W. Immunoglobulin metabolism. In : Receptors and the Action of Antibodies, ed. Metzger H. Washington DC : American Society of Microbiology, 1990 94 177.
21. Meno-Tetang GML, Lowe PJ. On the prediction of the human response: a recycled mechanistic PK/PD approach. Basic Clin Pharmacol Toxicol 2005 96 : 182 92.
22. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007 63 : 548 61.
23. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001 108 : 184 90.
24. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001 18 : 254 61. Erratum in Eur Respir J 2001; 18: 739-40.
25. Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004 34 : 632 8.
26. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009 123 : 107 13.
27. Ädelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000 106 : 253 9.
28. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws for biology. Science 1997 276 : 122 6.
29. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999 284 : 1677 9.
30. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NHG. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004 92 : 208 17.
31. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantitation limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008 35 : 401 21.
32. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007 82 : 17 20.
33. Riske F, Hakimi J, Mallmaci M, Griffin M, Pilson R, Tobkes N, Lin P, Danho W, Kochan J, Chizzonite R. High affinity human IgE receptor (FcRI) analysis of functional domains of the α-subunit with monoclonal antibodies. J Biol Chem 1991 266 : 11245 51.
34. Marcelletti JF, Katz DH. FcR epsilon+ lymphocytes and regulation of the IgE antibody system. I. A new class of molecules, termed IgE-induced regulants (EIR), which modulate FcR epsilon expression by lymphocytes. J Immunol 1984 133 : 2821 8.
35. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol 2004 114 : 527 30.
36. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004 113 : 297 302.
37. MacGlashan DW Jr., Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997 158 : 1438 45.